Projects / Programmes
Flow Cytometric Immunophenotyping in Diagnosis, Prognosis and Treatment of non-Hodgkin's Lymphomas
Code |
Science |
Field |
Subfield |
3.04.00 |
Medical sciences |
Oncology |
|
Code |
Science |
Field |
B200 |
Biomedical sciences |
Cytology, oncology, cancerology |
B520 |
Biomedical sciences |
General pathology, pathological anatomy |
non-Hodgkin lymphomas, immunophenotyping, flow cytometry, FNAB
Researchers (9)
Organisations (1)
no. |
Code |
Research organisation |
City |
Registration number |
No. of publicationsNo. of publications |
1. |
0302 |
Institute of Oncology Ljubljana |
Ljubljana |
5055733000 |
15,472 |
Abstract
Non-Hodgkin malignant lymphomas (NHL) are a group of morphologically and biologically different malignant diseases of the lymph nodes. In the new WHO classification 28 different histologic types of NHL are listed. This classification is based on morphologic, phenotypic and genetic changes. Conventional light microscopy is therefore of limited value in the diagnosis of NHL. The application of additional methods is mandatory not only for accurate diagnosis, but also for the evaluation of biological properties of NHL that are prognostic relevant and essential for the selection of treatment procedures. The leading hematopathologists believe that the immunophenotypic and genetic characteristics of lymphoma cells are the most promising in identifying the biologic potential of the tumor.
The cytopathological evaluation of lymphoproliferative diseases is routinely not used. However, we assume that the application of modern ancillary methods in cytopathology would substantially increase the diagnostic accuracy in this field. Particularly promising is flow-cytometric immunophenotyping, because cell samples obtained by fine needle aspiration biopsy (FNAB) are the most suitable for this method.
The objective of the proposed research project is to test if flow-cytometric immunophenotyping can
1). improve accuracy of FNAB in the diagnostics of NHL and determine significance of FNAB in pre-operative diagnostics of lymphomas,
2). define more accurately phenotypic properties of reactive and neoplastic lymphoproliferative lesions from FNAB samples,
3). assess the stability of immunophenotype and proliferative activity in NHL during the course of the treatment and the progression of the disease.
We expect that flow-cytometric immunophenotyping would be a great asset in the immunophenotyping of NHL in FNAB samples. It would improve the accuracy of cytopathologic examination and could also define the biological potential of the disease more precisely.